Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:SANA NASDAQ:SRRK NASDAQ:ZLAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$70.27+0.4%$65.37$47.86▼$107.37$3.86B0.28471,418 shs395,538 shsSANASana Biotechnology$5.13-0.2%$3.02$1.26▼$7.30$1.16B1.865.67 million shs6.56 million shsSRRKScholar Rock$39.11-1.5%$34.28$6.76▼$46.98$3.77B0.331.19 million shs748,196 shsZLABZai Lab$37.77+1.1%$35.10$16.01▼$44.34$4.15B0.99728,016 shs674,872 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx+2.52%-1.03%+9.98%+9.38%+10.78%SANASana Biotechnology+5.54%+18.71%+97.69%+190.40%-18.28%SRRKScholar Rock-0.68%-3.50%+19.32%+15.50%+331.63%ZLABZai Lab+1.00%+5.36%+3.78%+10.56%+92.73%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACLXArcellx2.6248 of 5 stars3.52.00.00.03.12.50.0SANASana Biotechnology3.2019 of 5 stars3.53.00.00.02.43.30.6SRRKScholar Rock3.3951 of 5 stars1.61.00.04.43.83.30.6ZLABZai Lab3.4779 of 5 stars3.45.00.00.03.51.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 3.07Buy$111.2358.29% UpsideSANASana Biotechnology 3.00Buy$9.1778.69% UpsideSRRKScholar Rock 3.13Buy$42.679.09% UpsideZLABZai Lab 2.80Moderate Buy$54.2843.70% UpsideCurrent Analyst Ratings BreakdownLatest SANA, SRRK, ZLAB, and ACLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2025SRRKScholar RockCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight7/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$12.006/30/2025ZLABZai LabLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$73.00 ➝ $75.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$5.006/18/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.006/17/2025ACLXArcellxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$110.006/16/2025ACLXArcellxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$115.006/3/2025SRRKScholar RockLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/14/2025SRRKScholar RockWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$50.005/9/2025ACLXArcellxScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$133.00 ➝ $93.004/24/2025SANASana BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.00(Data available from 7/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$107.94M35.88N/AN/A$8.41 per share8.36SANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ASRRKScholar Rock$33.19M111.89N/AN/A$3.94 per share9.93ZLABZai Lab$418.33M10.03N/AN/A$7.68 per share4.92Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$2.99N/AN/AN/A-211.46%-35.27%-22.73%8/14/2025 (Estimated)SANASana Biotechnology-$266.76M-$0.88N/AN/AN/AN/A-86.58%-44.49%8/6/2025 (Estimated)SRRKScholar Rock-$246.29M-$2.53N/AN/AN/AN/A-118.22%-82.01%8/6/2025 (Estimated)ZLABZai Lab-$257.10M-$2.49N/AN/AN/A-60.26%-33.35%-23.28%8/7/2025 (Estimated)Latest SANA, SRRK, ZLAB, and ACLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025ACLXArcellx-$1.03N/AN/AN/AN/AN/A8/14/2025Q2 2025SANASana Biotechnology-$0.20N/AN/AN/AN/AN/A8/7/2025Q2 2025ZLABZai Lab-$0.42N/AN/AN/A$125.66 millionN/A8/6/2025Q2 2025SRRKScholar Rock-$0.68N/AN/AN/AN/AN/A5/14/2025Q1 2025SRRKScholar Rock-$0.63-$0.67-$0.04-$0.67N/AN/A5/8/2025Q1 2025ACLXArcellx-$0.84-$1.13-$0.29-$1.13$19.51 million$8.13 million5/8/2025Q1 2025SANASana Biotechnology-$0.22-$0.20+$0.02-$0.21N/AN/A5/8/2025Q1 2025ZLABZai Lab-$0.50-$0.45+$0.05-$0.45$118.40 million$106.49 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ASRRKScholar RockN/AN/AN/AN/AN/AZLABZai LabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A4.934.93SANASana BiotechnologyN/A3.403.40SRRKScholar Rock0.1610.2510.25ZLABZai LabN/A3.263.09Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%SANASana Biotechnology88.23%SRRKScholar Rock91.08%ZLABZai Lab41.65%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%SANASana Biotechnology30.10%SRRKScholar Rock13.30%ZLABZai Lab4.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.11 million50.51 millionOptionableSANASana Biotechnology380225.48 million157.61 millionOptionableSRRKScholar Rock14094.95 million82.32 millionOptionableZLABZai Lab1,869111.08 million105.57 millionOptionableSANA, SRRK, ZLAB, and ACLX HeadlinesRecent News About These CompaniesZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Shares Acquired by Envestnet Asset Management Inc.July 24 at 3:24 AM | marketbeat.comZai Lab Limited (ZLAB) Stock Jumps 6.8%: Will It Continue to Soar?July 23 at 11:00 AM | zacks.comZai Lab (NASDAQ:ZLAB) Shares Gap Up - Here's What HappenedJuly 22 at 12:36 PM | marketbeat.comAllianz Asset Management GmbH Purchases 378,545 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 22 at 8:35 AM | marketbeat.comJennison Associates LLC Makes New Investment in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 20, 2025 | marketbeat.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - Here's WhyJuly 18, 2025 | marketbeat.comC WorldWide Group Holding A S Sells 40,000 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 18, 2025 | marketbeat.comMarks Group Wealth Management Inc Invests $373,000 in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 14, 2025 | marketbeat.comAlps Advisors Inc. Sells 12,097 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 12, 2025 | marketbeat.comZai Lab to Announce Second Quarter 2025 Financial Results and Recent Corporate Updates on August 7, 2025July 10, 2025 | businesswire.comZai Lab (NASDAQ:ZLAB) Shares Gap Down - What's Next?July 8, 2025 | marketbeat.com67,159 Shares in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Bought by Penserra Capital Management LLCJuly 8, 2025 | marketbeat.comPrincipal Financial Group Inc. Purchases 1,121,856 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB)July 5, 2025 | marketbeat.comYing Du Sells 7,072 Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) StockJuly 3, 2025 | marketbeat.comCantor Fitzgerald Lowers Earnings Estimates for Zai LabJuly 3, 2025 | marketbeat.comLeerink Partnrs Analysts Lift Earnings Estimates for Zai LabJuly 2, 2025 | marketbeat.comInsider Selling: Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells 6,918 Shares of StockJuly 2, 2025 | insidertrades.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Sells $245,727.36 in StockJuly 1, 2025 | marketbeat.comAmgen and Zai Lab’s trial of gastric cancer therapy meets primary endpointJuly 1, 2025 | finance.yahoo.comAmgen, Zai Lab succeed in gastric cancer studyJune 30, 2025 | msn.comZai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Given Consensus Recommendation of "Moderate Buy" by AnalystsJune 30, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSANA, SRRK, ZLAB, and ACLX Company DescriptionsArcellx NASDAQ:ACLX$70.27 +0.30 (+0.43%) Closing price 04:00 PM EasternExtended Trading$70.22 -0.05 (-0.08%) As of 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Sana Biotechnology NASDAQ:SANA$5.13 -0.01 (-0.19%) Closing price 04:00 PM EasternExtended Trading$5.22 +0.09 (+1.68%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Scholar Rock NASDAQ:SRRK$39.11 -0.60 (-1.51%) Closing price 04:00 PM EasternExtended Trading$39.10 -0.01 (-0.01%) As of 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.Zai Lab NASDAQ:ZLAB$37.77 +0.40 (+1.07%) Closing price 04:00 PM EasternExtended Trading$37.69 -0.08 (-0.21%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Krispy Kreme: A Meme Stock Sugar Rush or a Sustainable Treat? From Zero to Hero? Why GoPro's Rally Could Be More Than It Seems A Smokin’ Hot Entry Point for Chipotle Stock Opens in Q3 Alphabet’s Breakout Quarter Signals a New Leadership Phase Tesla Just Hit a Fork in the Road—Could the Bulls Lose Control? GE Vernova's Q2 Electrifies Stock, What's Next For This Top Name? Is Former Dividend Aristocrat AT&T a Buy After Q2 Earnings? What's Behind Opendoor Technologies' Rally? Is Meme Mania Back? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
